Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ.

Eur J Cancer. 2018 May;94:206-215. doi: 10.1016/j.ejca.2018.02.026. Epub 2018 Mar 22.

2.

Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).

Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z.

Breast Cancer. 2018 Feb 15. doi: 10.1007/s12282-018-0838-8. [Epub ahead of print]

PMID:
29450827
3.

Factors influencing the decision to attend screening for cancer in the UK: a meta-ethnography of qualitative research.

Young B, Bedford L, Kendrick D, Vedhara K, Robertson JFR, das Nair R.

J Public Health (Oxf). 2017 May 9:1-25. doi: 10.1093/pubmed/fdx026. [Epub ahead of print]

PMID:
28486650
4.

Treatment of the axilla in patients with primary breast cancer and low burden axillary disease: Limitations of the evidence from randomised controlled trials.

Robertson JF, Herrod PJ, Matthew J, Kilburn LS, Coles CE, Bradbury I.

Crit Rev Oncol Hematol. 2017 Feb;110:74-80. doi: 10.1016/j.critrevonc.2016.11.011. Epub 2016 Nov 25. Review.

PMID:
28109407
5.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?

Toss MS, Pinder SE, Green AR, Thomas J, Morgan DA, Robertson JF, Ellis IO, Rakha EA.

Histopathology. 2017 Apr;70(5):681-692. doi: 10.1111/his.13116. Epub 2016 Dec 20. Review.

PMID:
28000325
6.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ.

Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29.

PMID:
27908454
7.

Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ.

Mathew J, Karia R, Morgan DAL, Lee AHS, Ellis IO, Robertson JFR, Bello AM.

Breast. 2017 Feb;31:181-185. doi: 10.1016/j.breast.2016.11.002. Epub 2016 Nov 18.

PMID:
27871025
8.

Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.

Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF.

J Thorac Oncol. 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8.

9.

Human Blood Autoantibodies in the Detection of Colorectal Cancer.

Negm OH, Hamed MR, Schoen RE, Whelan RL, Steele RJ, Scholefield J, Dilnot EM, Shantha Kumara HM, Robertson JF, Sewell HF.

PLoS One. 2016 Jul 6;11(7):e0156971. doi: 10.1371/journal.pone.0156971. eCollection 2016.

10.

Reply to T. Reinert et al.

Ellis MJ, Robertson JF.

J Clin Oncol. 2016 Jun 1;34(16):1960-1. doi: 10.1200/JCO.2016.66.6727. Epub 2016 Mar 21. No abstract available.

PMID:
27001576
11.

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF.

J Clin Oncol. 2015 Nov 10;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831. Epub 2015 Sep 14.

12.

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Agrawal A, Robertson JF, Cheung KL, Gutteridge E, Ellis IO, Nicholson RI, Gee JM.

Int J Cancer. 2016 Jan 1;138(1):146-59. doi: 10.1002/ijc.29682. Epub 2015 Jul 30.

13.

Personalization of loco-regional care for primary breast cancer patients (part 2).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1301-5. doi: 10.2217/fon.15.66.

14.

Personalization of loco-regional care for primary breast cancer patients (part 1).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1297-300. doi: 10.2217/fon.15.65.

15.

Prehospital Breech Delivery with Fetal Head Entrapment -A Case Report and Review.

Robertson JF, Braude DA, Stonehocker J, Moreno J.

Prehosp Emerg Care. 2015 Jul-Sep;19(3):451-6. doi: 10.3109/10903127.2014.980476. Epub 2015 Feb 9. Review.

PMID:
25664593
16.

A good drug made better: the fulvestrant dose-response story.

Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM.

Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Review.

PMID:
25457991
17.

Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ, Ryder SJ, Holdenrieder S, Chapman CJ.

PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.

18.

Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.

Mathew J, Prinsloo P, Agrawal A, Gutteridge E, Marenah C, Robertson JF, Cheung KL.

Breast. 2014 Oct;23(5):567-72. doi: 10.1016/j.breast.2014.04.003. Epub 2014 May 27.

PMID:
24874285
19.

Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.

Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF.

Lung Cancer. 2014 Jan;83(1):51-5. doi: 10.1016/j.lungcan.2013.10.008. Epub 2013 Oct 22.

20.

Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer.

Healey GF, Lam S, Boyle P, Hamilton-Fairley G, Peek LJ, Robertson JF.

J Thorac Dis. 2013 Oct;5(5):618-25. doi: 10.3978/j.issn.2072-1439.2013.08.65.

21.

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF.

Ann Oncol. 2013 Oct;24(10):2543-8. doi: 10.1093/annonc/mdt216. Epub 2013 Jun 20.

PMID:
23788750
22.

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, Channon E, Hyman-Taylor P, Nicholson RI, Gee JM.

Breast Cancer Res. 2013 Mar 5;15(2):R18. doi: 10.1186/bcr3393.

23.

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA.

Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13.

PMID:
23414585
24.

Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test.

Macdonald IK, Murray A, Healey GF, Parsy-Kowalska CB, Allen J, McElveen J, Robertson C, Sewell HF, Chapman CJ, Robertson JF.

PLoS One. 2012;7(12):e51002. doi: 10.1371/journal.pone.0051002. Epub 2012 Dec 13.

25.

Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.

Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T.

Breast Cancer Res Treat. 2012 Dec;136(3):919-26. doi: 10.1007/s10549-012-2333-9. Epub 2012 Nov 11.

PMID:
23143284
26.

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ.

Breast Cancer Res Treat. 2012 Nov;136(2):503-11. doi: 10.1007/s10549-012-2192-4. Epub 2012 Oct 13.

PMID:
23065000
27.

Development and validation of a high throughput system for discovery of antigens for autoantibody detection.

Macdonald IK, Allen J, Murray A, Parsy-Kowalska CB, Healey GF, Chapman CJ, Sewell HF, Robertson JF.

PLoS One. 2012;7(7):e40759. doi: 10.1371/journal.pone.0040759. Epub 2012 Jul 18.

28.

EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF.

Tumour Biol. 2012 Oct;33(5):1319-26. doi: 10.1007/s13277-012-0379-2. Epub 2012 Apr 11.

29.

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.

Johnston SJ, Kenny FS, Syed BM, Robertson JF, Pinder SE, Winterbottom L, Ellis IO, Blamey RW, Cheung KL.

Ann Oncol. 2012 Sep;23(9):2296-300. doi: 10.1093/annonc/mdr630. Epub 2012 Feb 21.

PMID:
22357257
30.

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF.

Ann Oncol. 2012 Jun;23(6):1378-86. doi: 10.1093/annonc/mdr593. Epub 2012 Feb 8. Review.

PMID:
22317766
31.

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.

Knowlden JM, Gee JM, Barrow D, Robertson JF, Ellis IO, Nicholson RI, Hutcheson IR.

Breast Cancer Res. 2011 Sep 22;13(5):R93. doi: 10.1186/bcr3018.

32.

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer.

Agrawal A, Robertson JF, Cheung KL.

World J Surg Oncol. 2011 Sep 9;9:101. doi: 10.1186/1477-7819-9-101.

33.

EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.

Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF.

Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34. doi: 10.1158/1940-6207.CAPR-10-0328.

34.

Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference.

Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS.

Ann Surg Oncol. 2011 Oct;18(10):2885-92. doi: 10.1245/s10434-011-1666-7. Epub 2011 Mar 23.

35.

Controversies in Breast Cancer 2010. Session 6 introduction.

Robertson JF, Lønning PE.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S15. doi: 10.1186/bcr2744. No abstract available.

36.

Immunobiomarkers in small cell lung cancer: potential early cancer signals.

Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA, Maddison P, Robertson JF.

Clin Cancer Res. 2011 Mar 15;17(6):1474-80. doi: 10.1158/1078-0432.CCR-10-1363. Epub 2010 Dec 7.

37.

Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.

Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L.

Eur J Cancer. 2010 Nov;46(16):2936-42. doi: 10.1016/j.ejca.2010.08.005. Epub 2010 Sep 9.

PMID:
20832294
38.

Clinical validation of an autoantibody test for lung cancer.

Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF.

Ann Oncol. 2011 Feb;22(2):383-9. doi: 10.1093/annonc/mdq361. Epub 2010 Jul 30.

39.

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker.

Cheung KL, Iles RK, Robertson JF.

World J Surg Oncol. 2010 May 13;8:38. doi: 10.1186/1477-7819-8-38.

40.

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up.

Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL.

Crit Rev Oncol Hematol. 2011 Jun;78(3):260-4. doi: 10.1016/j.critrevonc.2010.04.006. Epub 2010 May 5.

PMID:
20447833
41.

Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer.

Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ.

Lung Cancer. 2010 Dec;70(3):335-9. doi: 10.1016/j.lungcan.2010.03.002. Epub 2010 Apr 3.

PMID:
20371131
42.

Technical validation of an autoantibody test for lung cancer.

Murray A, Chapman CJ, Healey G, Peek LJ, Parsons G, Baldwin D, Barnes A, Sewell HF, Fritsche HA, Robertson JF.

Ann Oncol. 2010 Aug;21(8):1687-93. doi: 10.1093/annonc/mdp606. Epub 2010 Feb 2.

43.

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

Gutteridge E, Robertson JF.

Breast Cancer Res. 2009;11 Suppl 3:S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18. No abstract available.

44.

Activity of fulvestrant in HER2-overexpressing advanced breast cancer.

Robertson JF, Steger GG, Neven P, Barni S, Gieseking F, Nolè F, Pritchard KI, O'Malley FP, Simon SD, Kaufman B, Petruzelka L.

Ann Oncol. 2010 Jun;21(6):1246-53. doi: 10.1093/annonc/mdp447. Epub 2009 Oct 29.

PMID:
19875750
45.

Neoadjuvant endocrine treatment in primary breast cancer - review of literature.

Mathew J, Asgeirsson KS, Jackson LR, Cheung KL, Robertson JF.

Breast. 2009 Dec;18(6):339-44. doi: 10.1016/j.breast.2009.09.012. Epub 2009 Oct 17. Review.

PMID:
19836953
46.

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ.

J Clin Oncol. 2009 Sep 20;27(27):4530-5. doi: 10.1200/JCO.2008.21.1136. Epub 2009 Aug 24.

PMID:
19704066
47.

Bone turnover markers in postmenopausal breast cancer treated with fulvestrant--a pilot study.

Agrawal A, Hannon RA, Cheung KL, Eastell R, Robertson JF.

Breast. 2009 Jun;18(3):204-7. doi: 10.1016/j.breast.2009.04.002. Epub 2009 May 21.

PMID:
19464177
48.

Chemoattraction and host preference of the gastropod parasitic nematode Phasmarhabditis hermaphrodita.

Rae RG, Robertson JF, Wilson MJ.

J Parasitol. 2009 Jun;95(3):517-26. doi: 10.1645/GE-1637.1.

PMID:
19117375
49.

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival.

Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI, Hurst HC.

J Pathol. 2009 Jan;217(1):32-41. doi: 10.1002/path.2430.

50.

A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.

Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM.

Glycobiology. 2008 Dec;18(12):1105-18. doi: 10.1093/glycob/cwn095. Epub 2008 Sep 25.

PMID:
18818422

Supplemental Content

Loading ...
Support Center